Omega Therapeutics

$9.25 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Omega Therapeutics

Omega Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused in a new class of DNA-sequence-targeting, mRNA-encoded therapeutics to fundamentally transform human medicine in the service of patients. It is developing OMEGA Epigenomic Programming platform is designed to coopt nature's universal operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation. The Company have deciphered the three-dimensional architecture of the human genome and its accompanying regulators, which are organized into distinct and evolutionarily conserved structures called Insulated Genomic Domains (IGDs). The OMEGA platform enables to systematically identify and validate thousands of DNA-sequence-based epigenomic zip codes within IGDs. The Company's pipeline consists of early-stage, preclinical programs that span regenerative medicine, multigenic diseases including immunology, oncology, and select monogenic diseases.

Stock Analysis

last close $9.68
1-mo return -30.4%
3-mo return -56.9%
avg daily vol. 82.04T
52-week high 31.41
52-week low 9.22
market cap. $509M
forward pe -
annual div. -
roe -
ltg forecast -
dividend yield -
annual rev. $--
inst own. 87.1%

Subscribe now for daily local and international financial news